Healthcare
Live Price
Offline$33.88
+3.58% today
1Y Change
-33.88%
Window
Jun 30, 2025 → Jun 23, 2026
Coverage: 246 bars · Jun 30, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hims & Hers Health, Inc. (HIMS) is a Healthcare stock with a market cap of $5.97B and listed on NYSE. The stock last traded around $33.88 and down 33.9% across the available one-year price window (Jun 30, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +59.0%, EPS growth of -1.7%, a dividend yield of 0.0%. What stands out right now is revenue +59.0%, EPS -1.7%, free cash flow -62.7% with operating margin 4.5% and ROIC 6.0%. Valuation already assumes a fairly strong business story at P/E 48.1 and price/sales 2.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines HIMS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
HIMS is 52.61 pts behind over the shared 1Y window.
HIMS had 68.93 pts deeper max drawdown than SPY.
HIMS beat SPY in 0 of 2 calendar years shown and trailed in 2.
HIMS
-33.88%
Normalized return
SPY
+18.73%
S&P 500
Excess Return
-52.61 pts
Relative to SPY
HIMS Max Drawdown
-78.06%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for HIMS and SPY.
| Year | HIMS | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -1.35% | +6.71% | -8.05 pts | SPY |
| 2025 | -33.72% | +11.19% | -44.91 pts | SPY |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$271.9M
-48.4% YoY
FY Net Income
-$107.7M
-63.9% YoY
Free Cash Flow
-$39.4M
-16.7% YoY
Revenue Growth
+59.0%
EPS Growth
-1.7%
Gross Margin
73.8%
Net Margin
5.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.3B | 1.5B | 872M | 527M | 272M |
| Gross Profit | 1.7B | 1.2B | 715M | 409M | 204M |
| Operating Income | 106M | 62M | -29M | -69M | -115M |
| EBITDA | 160M | 79M | -20M | -61M | -111M |
| Net Income | 128M | 126M | -24M | -66M | -108M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 229M | 221M | 97M | 47M | 72M |
| Total Assets | 2.2B | 708M | 441M | 366M | 421M |
| Total Liabilities | 1.6B | 231M | 97M | 55M | 86M |
| Shareholder Equity | 541M | 477M | 344M | 312M | 335M |
| Total Debt | 1.3B | 11M | 10M | 5M | 5M |
| Net Debt | 1.0B | -209M | -87M | -41M | -66M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
34M
-29.7% YoY
Capital Expenditures
5M
+30.9% YoY
Free Cash Flow
39M
-16.7% YoY
Key ratios
Gross Margin
73.8%
Operating Margin
4.5%
Net Margin
5.5%
ROE
23.0%
Debt / Equity
2.34x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.